Tumor suppressors in follicular lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 2014;89:429–436.
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.
   PubMed Web of Science ®Google Scholar
• Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012;122:3424–3231.
   PubMed Web of Science ®Google Scholar
• Hitz F, Ketterer N, Lohri A, et al. Diagnosis and treatment of follicular lymphoma. Swiss Med Wkly 2011;141:w13247.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Kersten MJ. Treatment strategies in advanced stage follicular lymphoma. Best Pract Res Clin Haematol 2011;24:187–201.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587–1594.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol 2011;24:147–163.
   PubMed Web of Science ®Google Scholar
• Schatz JH, Oricchio E, Puvvada SD, et al. Progress against follicular lymphoma. Curr Opin Hematol 2013;20:320–326.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228: 1440–1443.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439–43.
   PubMed Web of Science ®Google Scholar
• Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013;121:1604–1611.
   PubMed Web of Science ®Google Scholar
• Schuler F, Dolken L, Hirt C, et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 2009;124:958–963.
   PubMed Web of Science ®Google Scholar
• Tellier J, Menard C, Roulland S, et al. Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis? Blood 2014;123:3462–3465.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79–88.
   PubMed Web of Science ®Google Scholar
• Egle A, Harris AW, Bath ML, et al. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004;103:2276–2283.
   PubMed Web of Science ®Google Scholar
• Slack GW, Gascoyne RD. Next-generation sequencing discoveries in lymphoma. Adv Anat Pathol 2013;20:110–116.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014;46:176–181.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546–1558.
   PubMed Web of Science ®Google Scholar
• Stewart AK. Medicine. How thalidomide works against cancer. Science 2014;343:256–257.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia 2014;28:1388–1395.
   PubMed Web of Science ®Google Scholar
• Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823–837.
   PubMed Web of Science ®Google Scholar
• Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol 2011;11:478–488.
   PubMed Web of Science ®Google Scholar
• Herz HM, Garruss A, Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci 2013;38:621–639.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ando K, Suzuki T, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2014;165:768–776.
   PubMed Web of Science ®Google Scholar
• Roelfsema JH, Peters DJ. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 2007;9:1–16.
   PubMedGoogle Scholar
• Kung AL, Rebel VI, Bronson RT, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000;14:272–277.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181–185.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Graves AP, Ganji G, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012;109:2989–2994.
   PubMed Web of Science ®Google Scholar
• Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010;107:20980–20985.
   PubMed Web of Science ®Google Scholar
• Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011;117:2451–2459.
   PubMed Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013;23:677–692.
   PubMed Web of Science ®Google Scholar
• Berg T, Thoene S, Yap D, et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 2014;123:3914–3924.
   PubMed Web of Science ®Google Scholar
• Velichutina I, Shaknovich R, Geng H, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010;116:5247–5255.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014;6:130–140.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198–1203.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108–112.
   PubMed Web of Science ®Google Scholar
• Narlikar GJ, Sundaramoorthy R, Owen-Hughes T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 2013;154:490–503.
   PubMed Web of Science ®Google Scholar
• Li H, Kaminski MS, Li Y, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 2014;123:1487–1498.
   PubMed Web of Science ®Google Scholar
• Bouska A, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2014;123:1681–1690.
   PubMed Web of Science ®Google Scholar
• Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100–103.
   PubMed Web of Science ®Google Scholar
• Harshman SW, Young NL, Parthun MR, et al. H1 histones: current perspectives and challenges. Nucleic Acids Res 2013;41:9593–9609.
   PubMed Web of Science ®Google Scholar
• Hagman J, Ramirez J, Lukin K. B lymphocyte lineage specification, commitment and epigenetic control of transcription by early B cell factor 1. Curr Top Microbiol Immunol 2012;356:17–38.
   PubMed Web of Science ®Google Scholar
• Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265–275.
   PubMed Web of Science ®Google Scholar
• Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998;91:4677–4685.
   PubMed Web of Science ®Google Scholar
• Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998;91:2977–2984.
   PubMed Web of Science ®Google Scholar
• Alhejaily A, Day AG, Feilotter HE, et al. Inactivation of the CDKN2A tumor suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res 2014;20:1676–1686.
   PubMed Web of Science ®Google Scholar
• Schwaenen C, Viardot A, Berger H, et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009;48:39–54.
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Delaney A, Ben-Neriah S, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer 2010;49:669–681.
   PubMed Web of Science ®Google Scholar
• Fitzgibbon J, Iqbal S, Davies A, et al. Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia 2007;21:1514–1520.
   PubMed Web of Science ®Google Scholar
• Ross CW, Ouillette PD, Saddler CM, et al. Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res 2007;13:4777–4785.
   PubMed Web of Science ®Google Scholar
• Oricchio E, Ciriello G, Jiang M, et al. Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J Exp Med 2014;211:1379–1391.
   PubMed Web of Science ®Google Scholar
• Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006;5:44.
   PubMed Web of Science ®Google Scholar
• Baur AS, Shaw P, Burri N, et al. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94:1773–1781.
   PubMed Web of Science ®Google Scholar
• Alhejaily A, Wood B, Foster CJ, et al. Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. Hum Pathol 2011;42:972–982.
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B, Robledo M, Arranz E, et al. Hypermethylation of p15/ink4b/MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 1998;12:937–941.
   PubMed Web of Science ®Google Scholar
• O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126–3129.
   PubMed Web of Science ®Google Scholar
• Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994–2004.
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005;10:176–182.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–2440.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840–4845.
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009;113:137–148.
   PubMed Web of Science ®Google Scholar
• Oricchio E, Nanjangud G, Wolfe AL, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 2011; 147:554–564.
   PubMed Web of Science ®Google Scholar
• Oricchio E, Wendel HG. Functional genomics lead to new therapies in follicular lymphoma. Ann NY Acad Sci 2013;1293:18–24.
   PubMed Web of Science ®Google Scholar
• Dawson DW, Hong JS, Shen RR, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 2007;26: 4243–4252.
   PubMed Web of Science ®Google Scholar
• Holmberg J, Clarke DL, Frisen J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 2000;408:203–206.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165–180.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467–2475.
   PubMed Web of Science ®Google Scholar
• Rossi D, Ciardullo C, Gaidano G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Semin Cancer Biol 2013;23:422–430.
   PubMed Web of Science ®Google Scholar
• Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther 2013;35:1258–1270.
   PubMed Web of Science ®Google Scholar
• Hirsch B, Grunbaum M, Wagner F, et al. A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology. Histopathology 2012;60:E19–E27.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981–989.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717–721.
   PubMed Web of Science ®Google Scholar
• Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 2012;26:559–562.
   PubMed Web of Science ®Google Scholar
• Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010;70:9166–9174.
   PubMed Web of Science ®Google Scholar
• Pasero C, Speiser DE, Derre L, et al. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Curr Opin Pharmacol 2012;12:478–485.
   PubMed Web of Science ®Google Scholar
• Bjordahl RL, Steidl C, Gascoyne RD, et al. Lymphotoxin network pathways shape the tumor microenvironment. Curr Opin Immunol 2013;25:222–229.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012;109:3879–84.
   PubMed Web of Science ®Google Scholar
• Costello RT, Mallet F, Barbarat B, et al. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 2003;17:2500–2507.
   PubMed Web of Science ®Google Scholar
• Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354–2357.
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92:3018–3024.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Hu G, Offer SM, et al. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. Leukemia 2014;28:147–154.
   PubMed Web of Science ®Google Scholar
• Koyama M, Oka T, Ouchida M, et al. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest 2003;83:1849–1858.
   PubMed Web of Science ®Google Scholar
• Chim CS, Wong KY, Loong F, et al. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 2004;18:356–358.
   PubMed Web of Science ®Google Scholar
• Oka T, Yoshino T, Hayashi K, et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 2001;159:1495–1505.
   PubMed Web of Science ®Google Scholar
• Chim CS, Fung TK, Cheung WC, et al. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004;103:4630–4635.
   PubMed Web of Science ®Google Scholar
• Han Y, Amin HM, Frantz C, et al. Restoration of shp1 expression by 5-AZA-2’-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 2006;20:1602–1609.
   PubMed Web of Science ®Google Scholar
• Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006;134:366–384.
   PubMed Web of Science ®Google Scholar
• Mottok A, Renne C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 2009;114:4503–4506.
   PubMed Web of Science ®Google Scholar
• Kellis M, Wold B, Snyder MP, et al. Defining functional DNA elements in the human genome. Proc Natl Acad Sci USA 2014;111: 6131–6138.
   PubMed Web of Science ®Google Scholar
• Heintzman ND, Ren B. Finding distal regulatory elements in the human genome. Curr Opin Genet Dev 2009;19:541–549.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar